Abiopharma

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of Americas Most Successful Small-Cap Companies

CoyaTherapeutics - Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Halozyme - Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab withENHANZE®

(90% Positive) GRI BIO, INC. (GRI) Provides Update on modulators for Idiopathic Pulmonary Fibrosis

Ecolab Inc. - Ecolab Earns Double ‘A’ Rating from CDP for Leadership in Water and Climate Performance

(90% Positive) MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Provides Update on opportunities for inflammat

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621

Akanda Corp (AKAN) Files Form 6-K

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Collegium Provides 2026 Financial Guidance and Business Update

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook